A detailed history of Met Life Investment Management, LLC transactions in Cerus Corp stock. As of the latest transaction made, Met Life Investment Management, LLC holds 102,735 shares of CERS stock, worth $176,704. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,735
Previous 102,735 -0.0%
Holding current value
$176,704
Previous $180,000 1.11%
% of portfolio
0.0%
Previous 0.0%

Shares

55 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.62 - $2.04 $19,148 - $24,112
11,820 Added 13.0%
102,735 $180,000
Q1 2024

May 14, 2024

BUY
$1.66 - $2.42 $150,918 - $220,014
90,915 New
90,915 $171,000
Q2 2023

Apr 29, 2024

BUY
$1.79 - $2.9 $163,335 - $264,622
91,249 New
91,249 $224,000
Q1 2023

May 09, 2024

BUY
$2.65 - $3.81 $241,809 - $347,658
91,249 New
91,249 $271 Million
Q1 2023

May 15, 2023

BUY
$2.65 - $3.81 $21,920 - $31,516
8,272 Added 9.97%
91,249 $271,000
Q4 2022

May 10, 2024

SELL
$3.38 - $4.22 $31,917 - $39,849
-9,443 Reduced 10.22%
82,977 $302,000
Q4 2022

Jun 14, 2023

SELL
$3.38 - $4.22 $27,959 - $34,907
-8,272 Reduced 9.07%
82,977 $302,000
Q4 2022

Mar 22, 2023

SELL
$3.38 - $4.22 $31,917 - $39,849
-9,443 Reduced 10.22%
82,977 $302,000
Q4 2022

Feb 15, 2023

SELL
$3.38 - $4.22 $31,917 - $39,849
-9,443 Reduced 10.22%
82,977 $302,000
Q3 2022

May 10, 2024

BUY
$3.43 - $5.83 $57,860 - $98,346
16,869 Added 22.33%
92,420 $332,000
Q3 2022

Jun 14, 2023

BUY
$3.43 - $5.83 $4,016 - $6,826
1,171 Added 1.28%
92,420 $332,000
Q3 2022

Mar 22, 2023

BUY
$3.43 - $5.83 $57,860 - $98,346
16,869 Added 22.33%
92,420 $332,000
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $57,860 - $98,346
16,869 Added 22.33%
92,420 $333,000
Q2 2022

May 10, 2024

SELL
$4.41 - $5.69 $76,897 - $99,216
-17,437 Reduced 18.75%
75,551 $399,000
Q2 2022

Jun 20, 2023

SELL
$4.41 - $5.69 $69,228 - $89,321
-15,698 Reduced 17.2%
75,551 $399,000
Q2 2022

Mar 22, 2023

SELL
$4.41 - $5.69 $76,897 - $99,216
-17,437 Reduced 18.75%
75,551 $399,000
Q2 2022

Aug 11, 2022

SELL
$4.41 - $5.69 $76,897 - $99,216
-17,437 Reduced 18.75%
75,551 $400,000
Q1 2022

May 10, 2024

BUY
$4.81 - $6.99 $447,272 - $649,986
92,988 New
92,988 $510,000
Q1 2022

Jun 20, 2023

BUY
$4.81 - $6.99 $8,364 - $12,155
1,739 Added 1.91%
92,988 $510,000
Q1 2022

Mar 22, 2023

BUY
$4.81 - $6.99 $159,566 - $231,886
33,174 Added 55.46%
92,988 $510,000
Q1 2022

May 12, 2022

BUY
$4.81 - $6.99 $159,566 - $231,886
33,174 Added 55.46%
92,988 $511,000
Q4 2021

May 17, 2024

BUY
$5.97 - $7.93 $49,127 - $65,255
8,229 Added 15.95%
59,814 $407,000
Q4 2021

Jun 21, 2023

SELL
$5.97 - $7.93 $187,666 - $249,279
-31,435 Reduced 34.45%
59,814 $407,000
Q4 2021

Mar 22, 2023

BUY
$5.97 - $7.93 $49,127 - $65,255
8,229 Added 15.95%
59,814 $407,000
Q4 2021

Feb 15, 2022

BUY
$5.97 - $7.93 $49,127 - $65,255
8,229 Added 15.95%
59,814 $407,000
Q3 2021

May 17, 2024

SELL
$4.79 - $6.68 $62,935 - $87,768
-13,139 Reduced 20.3%
51,585 $314,000
Q3 2021

Jun 21, 2023

SELL
$4.79 - $6.68 $189,990 - $264,955
-39,664 Reduced 43.47%
51,585 $314,000
Q3 2021

Mar 22, 2023

SELL
$4.79 - $6.68 $62,935 - $87,768
-13,139 Reduced 20.3%
51,585 $314,000
Q3 2021

Nov 15, 2021

SELL
$4.79 - $6.68 $62,935 - $87,768
-13,139 Reduced 20.3%
51,585 $314,000
Q2 2021

Jun 21, 2023

SELL
$5.35 - $6.35 $141,908 - $168,433
-26,525 Reduced 29.07%
64,724 $382,000
Q1 2021

May 17, 2024

SELL
$5.68 - $7.87 $148,764 - $206,123
-26,191 Reduced 28.81%
64,724 $388,000
Q1 2021

Jun 26, 2023

SELL
$5.68 - $7.87 $150,662 - $208,751
-26,525 Reduced 29.07%
64,724 $389 Million
Q1 2021

Mar 22, 2023

SELL
$5.68 - $7.87 $21,248 - $29,441
-3,741 Reduced 5.46%
64,724 $388,000
Q1 2021

May 14, 2021

SELL
$5.68 - $7.87 $21,248 - $29,441
-3,741 Reduced 5.46%
64,724 $389,000
Q4 2020

May 24, 2024

SELL
$5.25 - $8.56 $11,508 - $18,763
-2,192 Reduced 3.1%
68,465 $473,000
Q4 2020

Jun 22, 2023

SELL
$5.25 - $8.56 $119,616 - $195,031
-22,784 Reduced 24.97%
68,465 $473,000
Q4 2020

Mar 22, 2023

SELL
$5.25 - $8.56 $11,508 - $18,763
-2,192 Reduced 3.1%
68,465 $473,000
Q4 2020

Feb 16, 2021

SELL
$5.25 - $8.56 $11,508 - $18,763
-2,192 Reduced 3.1%
68,465 $474,000
Q3 2020

Jun 26, 2023

SELL
$5.78 - $7.47 $119,021 - $153,822
-20,592 Reduced 22.57%
70,657 $442,000
Q2 2020

May 24, 2024

SELL
$4.5 - $7.02 $91,161 - $142,211
-20,258 Reduced 22.28%
70,657 $466 Million
Q2 2020

Jun 26, 2023

SELL
$4.5 - $7.02 $92,664 - $144,555
-20,592 Reduced 22.57%
70,657 $466,000
Q1 2020

Jul 12, 2023

SELL
$2.87 - $5.49 $59,099 - $113,050
-20,592 Reduced 22.57%
70,657 $328,000
Q1 2020

Mar 22, 2023

BUY
$2.87 - $5.49 $35,389 - $67,697
12,331 Added 21.14%
70,657 $328,000
Q1 2020

May 15, 2020

BUY
$2.87 - $5.49 $35,389 - $67,697
12,331 Added 21.14%
70,657 $329,000
Q4 2019

Jul 12, 2023

SELL
$3.84 - $4.86 $126,424 - $160,005
-32,923 Reduced 36.08%
58,326 $246,000
Q3 2019

Jul 12, 2023

SELL
$4.86 - $6.05 $160,005 - $199,184
-32,923 Reduced 36.08%
58,326 $300,000
Q2 2019

Jul 12, 2023

SELL
$4.51 - $6.6 $148,482 - $217,291
-32,923 Reduced 36.08%
58,326 $327,000
Q1 2019

Jul 13, 2023

SELL
$5.16 - $6.85 $169,882 - $225,522
-32,923 Reduced 36.08%
58,326 $363,000
Q4 2018

Jul 13, 2023

SELL
$4.89 - $7.16 $160,993 - $235,728
-32,923 Reduced 36.08%
58,326 $295,000
Q4 2018

Mar 22, 2023

SELL
$4.89 - $7.16 $162,406 - $237,797
-33,212 Reduced 36.28%
58,326 $295,000
Q4 2018

Feb 14, 2019

SELL
$4.89 - $7.16 $162,406 - $237,797
-33,212 Reduced 36.28%
58,326 $296,000
Q3 2018

Jul 13, 2023

SELL
$6.89 - $7.78 $226,839 - $256,140
-32,923 Reduced 36.08%
58,326 $420,000
Q3 2018

Mar 22, 2023

BUY
$6.89 - $7.78 $58,985 - $66,604
8,561 Added 10.32%
91,538 $659,000
Q3 2018

Nov 14, 2018

BUY
$6.89 - $7.78 $228,830 - $258,389
33,212 Added 56.94%
91,538 $660,000
Q4 2017

Feb 15, 2018

BUY
$2.76 - $3.95 $160,979 - $230,387
58,326
58,326 $197,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $305M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.